Edesa Biotech ( (EDSA) ) just unveiled an update.
On April 3, 2025, Edesa Biotech announced the resignation of Stephen Lemieux as Chief Financial Officer, effective May 1, 2025, to pursue other opportunities. He will continue as a senior financial advisor on a consulting basis. Peter J. Weiler has been appointed as the new CFO, bringing extensive experience from his previous roles in the biotechnology and pharmaceutical sectors. This transition is expected to enhance Edesa’s strategic financial management as the company advances its drug development pipeline.
More about Edesa Biotech
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company’s clinical pipeline targets Medical Dermatology and Respiratory therapeutic areas, with products like EB06 for vitiligo and EB05 for Acute Respiratory Distress Syndrome.
YTD Price Performance: 22.11%
Average Trading Volume: 1,954,529
Technical Sentiment Signal: Strong Buy
Current Market Cap: $16.22M
For detailed information about EDSA stock, go to TipRanks’ Stock Analysis page.